SELLAS Life Sciences Corporation, Inc. (Nasdaq: SLS), shares jumped 47.98% to 9.34 in the premarket session today even with no latest updates in the last 24 hours,
However, on December 7, 2020, a late-stage clinical biopharmaceutical business focused on the production of novel cancer immunotherapies. A China-based biotech giant 3D Medicines Inc. (‘3DMed’), said that they have entered into an Exclusive License Agreement Granting 3DMed the right to produce and commercialize the leading late-stage clinical candidate of SELLAS, galinpepimut-S (GPS), as well as its next-generation preclinical heptavalent immunotherapeutic, GPS+, through both medicinal and diagnostic applications in Greater China. Outside of the Greater China region, SELLAS holds sole rights to GPS and GPS+. Potential SELLAS payments under the deal could exceed license fees and incentive payments of $202 million, not counting possible royalty.
GPS is a revolutionary, theoretically first-in-class WT1 targeting artificially engineered, synthetic heteroclitic immunotherapy in the development of WT1 (Wilms Tumor Protein) antigen overexpression for hematological malignancies and solid tumors. In 2020, in patients with acute myeloid leukemia (AML) who have reached second full remission, SELLAS started a phase 3 clinical trial (REGAL study) of GPS.